August 2, 2015
Results of the Pan European Multi-Database Bladder Cancer Risk Characterization Study, a multi-database retrospective matched cohort study for pioglitazone containing medications, including Actos, with up to 10 years follow-up have recently been released, according to a press release from Takeda Pharmaceutical Company Limited.
“Actos is an important treatment option for patients with type 2 diabetes,” Alfonzo Perez, MD, vice president of clinical research at Takeda, said in the release. “These data further reinforce the positive benefit/risk profile for Actos. These long-term studies underscore Takeda’s commitment to ensuring physicians have the best available information to make treatment decisions.”